These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 21343343)

  • 41. Sexual dysfunction associated with second-generation antipsychotics in outpatients with schizophrenia or schizoaffective disorder: an empirical evaluation of olanzapine, risperidone, and quetiapine.
    Byerly MJ; Nakonezny PA; Bettcher BM; Carmody T; Fisher R; Rush AJ
    Schizophr Res; 2006 Sep; 86(1-3):244-50. PubMed ID: 16730951
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Olanzapine-induced neuroleptic malignant syndrome in a patient with paranoid schizophrenia.
    Srivastava A; Borkar HA; Chandak S
    Psychiatry Clin Neurosci; 2009 Feb; 63(1):119-21. PubMed ID: 19067992
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Olanzapine vs haloperidol for treatment of schizophrenia.
    Glazer WM
    JAMA; 2004 Mar; 291(9):1064-5; author reply 1065-6. PubMed ID: 14996766
    [No Abstract]   [Full Text] [Related]  

  • 44. Olanzapine vs haloperidol for treatment of schizophrenia.
    Amin M; Shukla VS
    JAMA; 2004 Mar; 291(9):1065; author reply 1065-6. PubMed ID: 14996767
    [No Abstract]   [Full Text] [Related]  

  • 45. Antipsychotic switching versus augmentation among early non-responders to risperidone or olanzapine in acute-phase schizophrenia.
    Hatta K; Otachi T; Fujita K; Morikawa F; Ito S; Tomiyama H; Abe T; Sudo Y; Takebayashi H; Yamashita T; Katayama S; Nakase R; Shirai Y; Usui C; Nakamura H; Ito H; Hirata T; Sawa Y;
    Schizophr Res; 2014 Sep; 158(1-3):213-22. PubMed ID: 25086659
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Prolongation of clozapine-induced neutropenia with olanzapine.
    Jagadheesan K; Mehrtens J
    Aust N Z J Psychiatry; 2007 Feb; 41(2):192. PubMed ID: 17464699
    [No Abstract]   [Full Text] [Related]  

  • 47. Prolongation of clozapine-induced leukopenia with olanzapine treatment.
    Sayin A; Cosar B
    Prog Neuropsychopharmacol Biol Psychiatry; 2006 Jul; 30(5):958-9. PubMed ID: 16631295
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Olanzapine-induced "restless arms syndrome".
    Konstantakopoulos G; Oulis P; Michalopoulou PG; Papadimitriou GN
    J Clin Psychopharmacol; 2009 Feb; 29(1):89-90. PubMed ID: 19142116
    [No Abstract]   [Full Text] [Related]  

  • 49. Comparison of metabolic changes in patients with schizophrenia during randomized treatment with intramuscular olanzapine long-acting injection versus oral olanzapine.
    McDonnell DP; Kryzhanovskaya LA; Zhao F; Detke HC; Feldman PD
    Hum Psychopharmacol; 2011 Aug; 26(6):422-33. PubMed ID: 21823172
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [A naturalistic, observational study of outpatients with schizophrenia: efficacy and safety results after 6 months. The International Schizophrenia Outpatient Health Outcomes study, IC-SOHO].
    István S; Agoston T; Tamás T; Zoltán J
    Neuropsychopharmacol Hung; 2007 Oct; 9(3):115-24. PubMed ID: 18399029
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Diabetes resolution following discontinuation of a second-generation antipsychotic.
    Strassnig M; Awerbuck J; Ganguli R
    Clin Schizophr Relat Psychoses; 2013 Jan; 6(4):202-3. PubMed ID: 23302450
    [No Abstract]   [Full Text] [Related]  

  • 52. Fatal water intoxication during olanzapine treatment: a case report.
    Nagasawa S; Yajima D; Torimitsu S; Abe H; Iwase H
    Leg Med (Tokyo); 2014 Mar; 16(2):89-91. PubMed ID: 24388043
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Long-term antipsychotic monotherapy for schizophrenia: disease burden and comparative outcomes for patients treated with olanzapine, quetiapine, risperidone, or haloperidol monotherapy in a pan-continental observational study.
    Dossenbach M; Pecenak J; Szulc A; Irimia V; Anders M; Logozar-Perkovic D; Peciukaitiene D; Kotler M; Smulevich AB; West TM; Lowry AJ; Treuer T
    J Clin Psychiatry; 2008 Dec; 69(12):1901-15. PubMed ID: 19012820
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Is there a real difference in severity of tardive dyskinesia between risperidone and olanzapine?
    Suzuki T; Takeuchi H; Watanabe K
    J Clin Psychiatry; 2010 Nov; 71(11):1553-4; author reply 1554. PubMed ID: 21114953
    [No Abstract]   [Full Text] [Related]  

  • 55. Reversible delayed onset olanzapine-associated leukopenia and neutropenia in a clozapine-naive patient on concomitant depot antipsychotic.
    Thinn SS; Liew E; May AL; Chua HC; Sim K
    J Clin Psychopharmacol; 2007 Aug; 27(4):394-5. PubMed ID: 17632225
    [No Abstract]   [Full Text] [Related]  

  • 56. EEG abnormalities under treatment with atypical antipsychotics: effects of olanzapine and amisulpride as compared to haloperidol.
    Pogarell O; Juckel G; Mulert C; Amann B; Möller HJ; Hegerl U
    Pharmacopsychiatry; 2004 Nov; 37(6):304-5. PubMed ID: 15551199
    [No Abstract]   [Full Text] [Related]  

  • 57. Ziprasidone-related agranulocytosis following olanzapine-induced neutropenia.
    Montgomery J
    Gen Hosp Psychiatry; 2006; 28(1):83-5. PubMed ID: 16377373
    [No Abstract]   [Full Text] [Related]  

  • 58. HTR2C polymorphisms, olanzapine-induced weight gain and antipsychotic-induced metabolic syndrome in schizophrenia patients: a meta-analysis.
    Ma X; Maimaitirexiati T; Zhang R; Gui X; Zhang W; Xu G; Hu G
    Int J Psychiatry Clin Pract; 2014 Oct; 18(4):229-42. PubMed ID: 25152019
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Case reports of postmarketing adverse event experiences with olanzapine intramuscular treatment in patients with agitation.
    Marder SR; Sorsaburu S; Dunayevich E; Karagianis JL; Dawe IC; Falk DM; Dellva MA; Carlson JL; Cavazzoni PA; Baker RW
    J Clin Psychiatry; 2010 Apr; 71(4):433-41. PubMed ID: 20156413
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Antipsychotic exposure and type 2 diabetes among patients with schizophrenia: a matched case-control study of California Medicaid claims.
    Lambert BL; Chou CH; Chang KY; Tafesse E; Carson W
    Pharmacoepidemiol Drug Saf; 2005 Jun; 14(6):417-25. PubMed ID: 15786516
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.